Martin Cadeiras, MD
Advanced Heart Failure and Transplant Cardiology · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 28 years
- Graduated 1998
Offices
1 location · Regents of the Univ of CA · 1,571 clinicians in this group
Hospitals listed: University of California Davis Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Cadeiras’s office at (916) 734-0655 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of California Davis Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.94 (1.18 to 2.71) · 3,010 cases | Worse | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 1.564 | Worse | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.6 to 8) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.9 to 14.5) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 127.46 (95.81 to 159.1) · 281 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.57) · 12,625 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.677 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.713 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,436 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.78 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 662 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 406 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,328 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,828 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.13 to 0.46) · 14,152 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.92 to 5.66) · 4,920 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.46 to 3.09) · 2,250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.06 to 3.09) · 4,696 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.46 (5.18 to 13.75) · 2,102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.35 (3.74 to 8.96) · 2,191 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.48 (1.19 to 3.77) · 1,169 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.826 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.669 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 751 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -25.8 · 127 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 758 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.6 · 477 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.4 to 14.9) · 2,643 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,768 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$58,267
Medicare paid this office $58,267 for 261 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 124 | $15,926 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 95 | $15,732 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $10,322 | $96 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,089 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,464 | $139 |
See all 8 services
| Return visit (30+ min) | 124 | $15,926 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 95 | $15,732 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $10,322 | $96 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,089 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,464 | $139 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 114 | $2,076 | $13 |
| New patient visit (45+ min) | 19 | $2,037 | $107 |
| Long return visit (40+ min) | 14 | $1,868 | $110 |
Who their Medicare patients are
261 Original Medicare patients in 2024. Average age 74 · Under 65 15% · 85 and older 19% · Women 40% · Also on Medicaid 38% · Health risk score 3.32. Above the middle of the specialty; the typical advanced heart failure and transplant cardiology clinician is at 2.53.
Conditions among them: High blood pressure 75% · Coronary heart disease 75% · Heart failure 75% · Chronic kidney disease 67% · Atrial fibrillation 62% · Diabetes 60% · COPD 34% · Depression 27% · Stroke 14% · Cancer 13% · Dementia 13%.
The office billed $318,613, Medicare allowed $75,187 and paid $58,267; for 884 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 261 | 884 | 74 | 3.32 | $318,613 | $58,267 |
| 2023 | 237 | 743 | 73 | 3.14 | $285,905 | $56,564 |
| 2022 | 213 | 700 | 72 | 3.23 | $290,163 | $55,966 |
| 2021 | 263 | 1,081 | 72 | 3.13 | $399,171 | $88,117 |
| 2020 | 251 | 971 | 72 | 3.32 | $333,003 | $75,264 |
| 2019 | 217 | 1,093 | 70 | 3.34 | $381,735 | $87,879 |
| 2018 | 262 | 802 | 68 | 3.32 | $377,308 | $60,322 |
| 2017 | 250 | 864 | 67 | 3.58 | $550,247 | $91,525 |
| 2016 | 205 | 633 | 66 | 3.67 | $323,552 | $63,651 |
| 2015 | 586 | 1,236 | 70 | 3.23 | $275,094 | $60,669 |
| 2014 | 839 | 1,660 | 72 | 2.26 | $271,294 | $66,200 |
| 2013 | 571 | 1,161 | 70 | 2.36 | $265,140 | $63,382 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 90 | $19,918 | $66 |
| Return visit (30+ min) | 104 | $14,494 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $7,823 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $5,294 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $2,887 | $144 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $1,338 | $41 |
| Evaluation of lower heart chamber assist device | 11 | $617 | $32 |
2022: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $25,747 | $84 |
| Return visit (30+ min) | 113 | $16,350 | $75 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,760 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,596 | $162 |
| Evaluation of lower heart chamber assist device | 11 | $1,539 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,053 | $58 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 129 | $44,665 | $85 |
| Return visit (30+ min) | 119 | $21,646 | $80 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,686 | $112 |
| Long return visit (40+ min) | 24 | $3,514 | $121 |
| Evaluation of lower heart chamber assist device | 23 | $3,362 | $32 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,332 | $167 |
| Return visit (30+ min) | 13 | $1,809 | $79 |
2020: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 119 | $37,226 | $86 |
| Return visit (30+ min) | 115 | $14,372 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,359 | $167 |
| Long return visit (40+ min) | 37 | $3,534 | $82 |
| Evaluation of lower heart chamber assist device | 26 | $3,272 | $38 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,726 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,430 | $57 |
| Return visit (30+ min) | 12 | $912 | $65 |
| Short return visit (20+ min) | 18 | $848 | $42 |
2019: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $40,948 | $86 |
| Return visit (30+ min) | 104 | $12,030 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,284 | $166 |
| Long return visit (40+ min) | 65 | $8,505 | $85 |
| Evaluation of lower heart chamber assist device | 23 | $4,984 | $38 |
| Critical care, first 30-74 minutes | 17 | $4,201 | $183 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,034 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,926 | $60 |
| New patient visit (45+ min) | 13 | $1,384 | $106 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $999 | $83 |
2018: 7 services
| Return visit (30+ min) | 184 | $22,232 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 52 | $15,944 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,190 | $168 |
| Evaluation of lower heart chamber assist device | 26 | $4,081 | $38 |
| Long return visit (40+ min) | 15 | $1,627 | $90 |
| Short return visit (20+ min) | 23 | $1,339 | $42 |
| New patient visit (45+ min) | 14 | $1,291 | $92 |
2017: 6 services
| Critical care, first 30-74 minutes | 29 | $46,012 | $188 |
| Return visit (30+ min) | 179 | $22,924 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $11,452 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,789 | $172 |
| New patient visit (45+ min) | 12 | $1,321 | $110 |
| Short return visit (20+ min) | 11 | $433 | $39 |
2016: 6 services
| Critical care, first 30-74 minutes | 33 | $24,124 | $188 |
| Return visit (30+ min) | 135 | $19,098 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $7,311 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,054 | $169 |
| New patient visit (45+ min) | 23 | $2,465 | $107 |
| Short return visit (20+ min) | 11 | $477 | $40 |
2015: 9 services
| Critical care, first 30-74 minutes | 18 | $17,090 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $11,112 | $87 |
| Return visit (30+ min) | 95 | $9,983 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,138 | $171 |
| Biopsy of heart muscle | 16 | $5,362 | $192 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 446 | $4,988 | $7 |
| Insertion of tube in right heart chambers for measurement | 17 | $1,720 | $69 |
| New patient visit (45+ min) | 11 | $1,203 | $109 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,089 | $91 |
2014: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $33,037 | $87 |
| Return visit (30+ min) | 65 | $8,632 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,865 | $167 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 722 | $7,070 | $7 |
| Biopsy of heart muscle | 12 | $3,041 | $190 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,074 | $90 |
| Insertion of tube in right heart chambers for measurement | 11 | $1,162 | $73 |
2013: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $28,369 | $84 |
| Long return visit (40+ min) | 49 | $7,619 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,731 | $164 |
| Biopsy of heart muscle | 15 | $4,602 | $184 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 427 | $3,326 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,336 | $58 |
| Return visit (30+ min) | 31 | $2,260 | $58 |
| Insertion of tube in right heart chambers for measurement | 17 | $1,858 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,446 | $111 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,233 | $82 |
| Hospital discharge day management, 30 minutes or less | 16 | $953 | $60 |
Medicaid work
$3,046 in 2021
Medicaid paid $3,046 for 53 billed services this clinician did in 2021, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 39 | $2,497 |
| Return visit (30+ min) | 14 | $550 |
| 2021 | 53 | 2 | 14 | $3,046 |
| 2020 | 25 | 1 | 13 | $1,180 |
| 2018 | 141 | 4 | 19 | $4,680 |
See the largest Medicaid services in earlier years
2020
| Return visit (30+ min) | 25 | $1,180 |
2018
| Return visit (30+ min) | 101 | $4,363 |
| Natriuretic peptide (heart and blood vessel protein) level | 14 | $169 |
| COMPREHENSIVE METABOLIC PANEL | 14 | $110 |
| Measurement of magnesium | 12 | $38 |
Drugs they prescribed that Part D paid
$2,113,452
Pharmacies billed $2,113,452 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,146) in 2024. At or below the middle of the specialty; the typical advanced heart failure and transplant cardiology clinician is at 0%.
1,221 generic and 925 brand-name prescriptions · $2,113,452 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyndamax | 44 | $990,862 | $22,520 |
| Entresto | 264 | $303,815 | $1,151 |
| Jardiance | 186 | $217,678 | $1,170 |
| Eliquis | 129 | $151,246 | $1,172 |
| Opsumit | 12 | $131,083 | $10,924 |
See all 32 drugs
| Vyndamax | 44 | $990,862 | $22,520 |
| Entresto | 264 | $303,815 | $1,151 |
| Jardiance | 186 | $217,678 | $1,170 |
| Eliquis | 129 | $151,246 | $1,172 |
| Opsumit | 12 | $131,083 | $10,924 |
| Farxiga | 73 | $78,820 | $1,080 |
| Ozempic | 62 | $63,861 | $1,030 |
| Xarelto | 18 | $28,845 | $1,603 |
| Wegovy | 13 | $17,255 | $1,327 |
| Veltassa | 12 | $14,376 | $1,198 |
| Sildenafil Citrate | 17 | $9,123 | $537 |
| Metoprolol | 197 | $3,223 | $16 |
| Eplerenone | 36 | $3,045 | $85 |
| Bumetanide | 43 | $2,928 | $68 |
| Spironolactone | 206 | $2,079 | $10 |
| Torsemide | 19 | $1,091 | $57 |
| Atorvastatin | 128 | $1,059 | $8 |
| Carvedilol | 97 | $1,024 | $11 |
| Rosuvastatin | 40 | $954 | $24 |
| Potassium Chloride | 15 | $714 | $48 |
| Amiodarone | 42 | $659 | $16 |
| Bisoprolol | 19 | $495 | $26 |
| Furosemide | 85 | $353 | $4 |
| Clopidogrel | 18 | $325 | $18 |
| Losartan | 49 | $317 | $6 |
| Ezetimibe | 21 | $213 | $10 |
| Hydralazine | 19 | $206 | $11 |
| Digoxin | 15 | $197 | $13 |
| Lisinopril | 33 | $145 | $4 |
| Isosorbide Mononitrate Er | 12 | $106 | $9 |
| Pravastatin | 11 | $67 | $6 |
| Amlodipine Besylate | 12 | $14 | $1 |
Year by year
| 2024 | 2,146 | 179 | 0% (0) | 43% | $2,113,452 |
| 2023 | 1,787 | 137 | 0% (0) | None | $1,524,389 |
| 2022 | 2,044 | 145 | 0% (0) | None | $1,556,725 |
| 2021 | 2,106 | 152 | 0% (0) | None | $2,068,889 |
| 2020 | 1,672 | 137 | 0% (0) | 26% | $1,528,047 |
| 2019 | 1,522 | 157 | 0% (0) | 21% | $819,590 |
| 2018 | 1,329 | 191 | None | None | $153,267 |
| 2017 | 1,209 | 155 | 0% (0) | None | $128,522 |
| 2016 | 1,079 | 126 | 0% (0) | None | $64,332 |
| 2015 | 844 | 90 | 0% (0) | None | $74,084 |
| 2014 | 765 | 92 | None | 23% | $76,777 |
| 2013 | 617 | 100 | None | None | $50,091 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Vyndamax | 34 | $637,329 | $18,745 |
| Entresto | 204 | $262,907 | $1,289 |
| Jardiance | 134 | $132,654 | $990 |
| Eliquis | 94 | $114,570 | $1,219 |
| Farxiga | 48 | $71,209 | $1,484 |
| Ozempic | 52 | $61,732 | $1,187 |
| Xarelto | 11 | $19,856 | $1,805 |
| Vascepa | 22 | $3,987 | $181 |
| Eplerenone | 21 | $3,886 | $185 |
| Metoprolol | 111 | $3,381 | $30 |
| Torsemide | 39 | $2,615 | $67 |
| Spironolactone | 179 | $2,456 | $14 |
| Mexiletine | 14 | $2,257 | $161 |
| Bumetanide | 31 | $1,991 | $64 |
| Atorvastatin | 102 | $1,760 | $17 |
| Carvedilol | 92 | $1,542 | $17 |
| Rosuvastatin | 32 | $1,303 | $41 |
| Clonidine | 12 | $913 | $76 |
| Amiodarone | 29 | $699 | $24 |
| Bisoprolol | 18 | $620 | $34 |
| Furosemide | 68 | $600 | $9 |
| Digoxin | 19 | $443 | $23 |
| Losartan | 41 | $441 | $11 |
| Amlodipine Besylate | 21 | $395 | $19 |
| Clopidogrel | 16 | $312 | $20 |
| Hydralazine | 16 | $292 | $18 |
| Allopurinol | 15 | $192 | $13 |
| Simvastatin | 11 | $135 | $12 |
| Lisinopril | 19 | $131 | $7 |
| Fluconazole | 24 | $129 | $5 |
| Metformin | 24 | $78 | $3 |
2022: 41 drugs
| Vyndamax | 43 | $893,539 | $20,780 |
| Entresto | 232 | $234,707 | $1,012 |
| Eliquis | 123 | $117,436 | $955 |
| Farxiga | 80 | $68,634 | $858 |
| Jardiance | 61 | $55,559 | $911 |
| Ozempic | 41 | $42,041 | $1,025 |
| Xarelto | 16 | $19,567 | $1,223 |
| Verquvo | 12 | $13,289 | $1,107 |
| Everolimus | 12 | $9,205 | $767 |
| Eplerenone | 21 | $4,701 | $224 |
| Bumetanide | 51 | $3,886 | $76 |
| Metoprolol | 107 | $2,201 | $21 |
| Atorvastatin | 127 | $1,411 | $11 |
| Rosuvastatin | 34 | $1,361 | $40 |
| Potassium Chloride | 39 | $1,340 | $34 |
| Spironolactone | 168 | $1,339 | $8 |
| Carvedilol | 120 | $1,293 | $11 |
| Mexiletine | 11 | $1,194 | $109 |
| Amiodarone | 50 | $1,121 | $22 |
| Torsemide | 26 | $973 | $37 |
| Ezetimibe | 18 | $962 | $53 |
| Losartan | 57 | $626 | $11 |
| Pantoprazole | 33 | $602 | $18 |
| Digoxin | 29 | $526 | $18 |
| Bisoprolol | 17 | $355 | $21 |
| Hydralazine | 25 | $350 | $14 |
| Tamsulosin | 22 | $335 | $15 |
| Furosemide | 72 | $331 | $5 |
| Warfarin | 12 | $323 | $27 |
| Allopurinol | 35 | $224 | $6 |
| Metoprolol | 11 | $202 | $18 |
| Clopidogrel | 12 | $168 | $14 |
| Prednisone | 15 | $138 | $9 |
| Lisinopril | 17 | $135 | $8 |
| Propranolol | 12 | $115 | $10 |
| Clonidine | 12 | $95 | $8 |
| Amlodipine Besylate | 14 | $85 | $6 |
| Diltiazem | 13 | $82 | $6 |
| Escitalopram | 13 | $57 | $4 |
| Fluconazole | 11 | $45 | $4 |
| Simvastatin | 19 | $32 | $2 |
2021: 32 drugs
| Vyndamax | 64 | $1,235,411 | $19,303 |
| Entresto | 277 | $213,131 | $769 |
| Eliquis | 113 | $99,467 | $880 |
| Farxiga | 106 | $74,481 | $703 |
| Jardiance | 71 | $54,086 | $762 |
| Xarelto | 22 | $25,469 | $1,158 |
| Tadalafil | 12 | $19,310 | $1,609 |
| Ozempic | 22 | $19,038 | $865 |
| Bumetanide | 46 | $3,560 | $77 |
| Eplerenone | 13 | $2,425 | $187 |
| Metoprolol | 128 | $2,417 | $19 |
| Carvedilol | 173 | $1,736 | $10 |
| Atorvastatin | 131 | $1,559 | $12 |
| Spironolactone | 202 | $1,455 | $7 |
| Potassium Chloride | 43 | $1,405 | $33 |
| Ezetimibe | 27 | $1,370 | $51 |
| Torsemide | 27 | $1,037 | $38 |
| Sildenafil Citrate | 23 | $867 | $38 |
| Amiodarone | 44 | $830 | $19 |
| Rosuvastatin | 11 | $677 | $62 |
| Losartan | 41 | $586 | $14 |
| Bisoprolol | 28 | $547 | $20 |
| Digoxin | 28 | $486 | $17 |
| Furosemide | 100 | $462 | $5 |
| Hydralazine | 22 | $379 | $17 |
| Pravastatin | 16 | $301 | $19 |
| Pantoprazole | 17 | $284 | $17 |
| Benazepril | 12 | $258 | $21 |
| Diltiazem | 13 | $185 | $14 |
| Allopurinol | 20 | $158 | $8 |
| Lisinopril | 24 | $135 | $6 |
| Simvastatin | 22 | $93 | $4 |
2020: 34 drugs
| Vyndamax | 26 | $497,527 | $19,136 |
| Vyndaqel | 24 | $461,233 | $19,218 |
| Opsumit | 21 | $219,421 | $10,449 |
| Entresto | 109 | $83,735 | $768 |
| Eliquis | 73 | $63,903 | $875 |
| Farxiga | 22 | $12,424 | $565 |
| Jardiance | 17 | $9,072 | $534 |
| Eplerenone | 24 | $4,430 | $185 |
| Bumetanide | 52 | $3,119 | $60 |
| Metoprolol | 100 | $2,221 | $22 |
| Atorvastatin | 137 | $1,933 | $14 |
| Telmisartan | 21 | $1,544 | $74 |
| Carvedilol | 129 | $1,287 | $10 |
| Sildenafil Citrate | 24 | $1,267 | $53 |
| Potassium Chloride | 33 | $1,083 | $33 |
| Spironolactone | 131 | $859 | $7 |
| Torsemide | 24 | $669 | $28 |
| Isosorbide Mononitrate Er | 27 | $636 | $24 |
| Losartan | 48 | $535 | $11 |
| Hydralazine | 21 | $501 | $24 |
| Digoxin | 41 | $489 | $12 |
| Furosemide | 86 | $446 | $5 |
| Amiodarone | 41 | $441 | $11 |
| Bisoprolol | 21 | $379 | $18 |
| Propranolol | 16 | $322 | $20 |
| Pantoprazole | 28 | $283 | $10 |
| Mycophenolate Mofetil | 12 | $275 | $23 |
| Lisinopril | 48 | $243 | $5 |
| Finasteride | 14 | $211 | $15 |
| Diltiazem | 13 | $204 | $16 |
| Allopurinol | 16 | $201 | $13 |
| Tamsulosin | 16 | $184 | $11 |
| Simvastatin | 27 | $92 | $3 |
| Prednisone | 12 | $81 | $7 |
2019: 37 drugs
| Vyndaqel | 18 | $345,951 | $19,220 |
| Opsumit | 13 | $132,794 | $10,215 |
| Eliquis | 68 | $43,689 | $642 |
| Entresto | 43 | $30,306 | $705 |
| Vascepa | 11 | $4,372 | $397 |
| Colcrys | 12 | $4,333 | $361 |
| Bumetanide | 47 | $2,762 | $59 |
| Metoprolol | 84 | $2,397 | $29 |
| Eplerenone | 16 | $1,868 | $117 |
| Carvedilol | 123 | $1,830 | $15 |
| Potassium Chloride | 78 | $1,794 | $23 |
| Atorvastatin | 104 | $1,640 | $16 |
| Sildenafil Citrate | 22 | $1,417 | $64 |
| Rosuvastatin | 21 | $1,370 | $65 |
| Torsemide | 24 | $892 | $37 |
| Spironolactone | 107 | $834 | $8 |
| Fluconazole | 20 | $763 | $38 |
| Tacrolimus | 14 | $761 | $54 |
| Losartan | 49 | $543 | $11 |
| Pravastatin | 16 | $427 | $27 |
| Lisinopril | 71 | $411 | $6 |
| Isosorbide Mononitrate Er | 18 | $387 | $22 |
| Furosemide | 66 | $371 | $6 |
| Mycophenolate Mofetil | 12 | $327 | $27 |
| Amiodarone | 29 | $303 | $10 |
| Digoxin | 29 | $302 | $10 |
| Propranolol | 25 | $288 | $12 |
| Pantoprazole | 20 | $251 | $13 |
| Warfarin | 13 | $196 | $15 |
| Allopurinol | 13 | $147 | $11 |
| Metoprolol | 20 | $113 | $6 |
| Simvastatin | 23 | $106 | $5 |
| Tamsulosin | 12 | $90 | $8 |
| Prednisone | 12 | $86 | $7 |
| Amlodipine Besylate | 20 | $74 | $4 |
| Trazodone | 13 | $65 | $5 |
| Ranitidine | 11 | $53 | $5 |
2018: 29 drugs
| Entresto | 37 | $21,495 | $581 |
| Xarelto | 25 | $20,132 | $805 |
| Eliquis | 39 | $17,828 | $457 |
| Valganciclovir | 13 | $11,235 | $864 |
| Corlanor | 15 | $9,354 | $624 |
| Metoprolol | 59 | $1,829 | $31 |
| Rosuvastatin | 40 | $1,764 | $44 |
| Atorvastatin | 72 | $1,372 | $19 |
| Carvedilol | 144 | $1,319 | $9 |
| Tacrolimus | 19 | $1,226 | $65 |
| Potassium Chloride | 28 | $1,217 | $43 |
| Fluconazole | 34 | $1,216 | $36 |
| Ezetimibe | 13 | $1,197 | $92 |
| Pravastatin | 50 | $1,060 | $21 |
| Gabapentin | 24 | $836 | $35 |
| Spironolactone | 69 | $649 | $9 |
| Furosemide | 105 | $592 | $6 |
| Lisinopril | 95 | $551 | $6 |
| Losartan | 43 | $377 | $9 |
| Prednisone | 17 | $268 | $16 |
| Valsartan | 13 | $242 | $19 |
| Clopidogrel | 12 | $238 | $20 |
| Warfarin | 14 | $238 | $17 |
| Amiodarone | 21 | $203 | $10 |
| Metoprolol | 60 | $186 | $3 |
| Simvastatin | 31 | $177 | $6 |
| Pantoprazole | 18 | $158 | $9 |
| Hydralazine | 14 | $143 | $10 |
| Amlodipine Besylate | 11 | $35 | $3 |
2017: 27 drugs
| Xarelto | 35 | $15,108 | $432 |
| Entresto | 21 | $10,732 | $511 |
| Valganciclovir | 15 | $10,358 | $691 |
| Eliquis | 19 | $8,763 | $461 |
| Metoprolol | 53 | $2,465 | $47 |
| Tacrolimus | 17 | $2,154 | $127 |
| Mycophenolate Mofetil | 24 | $2,027 | $84 |
| Rosuvastatin | 39 | $1,954 | $50 |
| Atorvastatin | 84 | $1,323 | $16 |
| Potassium Chloride | 29 | $1,314 | $45 |
| Fluconazole | 26 | $1,094 | $42 |
| Carvedilol | 111 | $1,054 | $9 |
| Pravastatin | 66 | $1,042 | $16 |
| Spironolactone | 69 | $676 | $10 |
| Lisinopril | 77 | $639 | $8 |
| Torsemide | 17 | $451 | $27 |
| Furosemide | 74 | $377 | $5 |
| Losartan | 43 | $359 | $8 |
| Hydralazine | 18 | $308 | $17 |
| Isosorbide Dinitrate | 11 | $305 | $28 |
| Warfarin | 21 | $299 | $14 |
| Prednisone | 17 | $282 | $17 |
| Pantoprazole | 30 | $202 | $7 |
| Simvastatin | 19 | $183 | $10 |
| Metoprolol | 43 | $144 | $3 |
| Amlodipine Besylate | 20 | $89 | $4 |
| Benazepril | 11 | $69 | $6 |
2016: 27 drugs
| Prograf | 16 | $6,584 | $411 |
| Effient | 11 | $4,218 | $383 |
| Crestor | 15 | $3,800 | $253 |
| Mycophenolate Mofetil | 34 | $3,471 | $102 |
| Tacrolimus | 29 | $3,156 | $109 |
| Metoprolol | 46 | $1,583 | $34 |
| Esomeprazole Magnesium | 12 | $1,359 | $113 |
| Pravastatin | 77 | $1,106 | $14 |
| Fluconazole | 29 | $1,002 | $35 |
| Carvedilol | 100 | $913 | $9 |
| Diltiazem 12hr Er | 11 | $789 | $72 |
| Spironolactone | 71 | $767 | $11 |
| Atorvastatin | 57 | $746 | $13 |
| Allopurinol | 24 | $583 | $24 |
| Lisinopril | 88 | $546 | $6 |
| Potassium Chloride | 22 | $539 | $24 |
| Furosemide | 77 | $485 | $6 |
| Hydralazine | 14 | $394 | $28 |
| Isosorbide Mononitrate Er | 14 | $390 | $28 |
| Metoprolol | 37 | $279 | $8 |
| Pantoprazole | 15 | $210 | $14 |
| Losartan | 20 | $203 | $10 |
| Amlodipine Besylate | 26 | $201 | $8 |
| Prednisone | 15 | $168 | $11 |
| Simvastatin | 20 | $118 | $6 |
| Warfarin | 12 | $72 | $6 |
| Sulfamethoxazole-Trimethoprim | 14 | $49 | $4 |
2015: 22 drugs
| Crestor | 21 | $5,653 | $269 |
| Mycophenolic Acid | 11 | $3,875 | $352 |
| Fluconazole | 29 | $2,236 | $77 |
| Tacrolimus | 11 | $1,041 | $95 |
| Mycophenolate Mofetil | 15 | $955 | $64 |
| Clotrimazole | 15 | $725 | $48 |
| Atorvastatin | 30 | $644 | $21 |
| Carvedilol | 77 | $454 | $6 |
| Pravastatin | 27 | $452 | $17 |
| Furosemide | 65 | $408 | $6 |
| Metoprolol | 40 | $406 | $10 |
| Hydralazine | 23 | $372 | $16 |
| Metoprolol | 12 | $263 | $22 |
| Spironolactone | 41 | $254 | $6 |
| Lisinopril | 43 | $237 | $6 |
| Pantoprazole | 28 | $226 | $8 |
| Sulfamethoxazole-Trimethoprim | 30 | $213 | $7 |
| Alendronate | 28 | $211 | $8 |
| Amlodipine Besylate | 31 | $191 | $6 |
| Losartan | 28 | $181 | $6 |
| Prednisone | 13 | $180 | $14 |
| Amiodarone | 18 | $134 | $7 |
2014: 22 drugs
| Valcyte | 11 | $28,246 | $2,568 |
| Myfortic | 11 | $8,608 | $783 |
| Crestor | 17 | $3,548 | $209 |
| Isosorbide Dinitrate | 15 | $1,480 | $99 |
| Fluconazole | 11 | $895 | $81 |
| Atorvastatin | 39 | $726 | $19 |
| Hydralazine | 35 | $642 | $18 |
| Carvedilol | 52 | $514 | $10 |
| Metoprolol | 18 | $427 | $24 |
| Clotrimazole | 11 | $402 | $37 |
| Furosemide | 41 | $247 | $6 |
| Prednisone | 16 | $245 | $15 |
| Pravastatin | 14 | $212 | $15 |
| Clopidogrel | 13 | $209 | $16 |
| Losartan | 19 | $198 | $10 |
| Lisinopril | 51 | $197 | $4 |
| Pantoprazole | 24 | $192 | $8 |
| Spironolactone | 25 | $146 | $6 |
| Sulfamethoxazole-Trimethoprim | 18 | $139 | $8 |
| Metoprolol | 32 | $137 | $4 |
| Amlodipine Besylate | 15 | $114 | $8 |
| Simvastatin | 11 | $75 | $7 |
2013: 16 drugs
| Diovan | 11 | $2,237 | $203 |
| Clopidogrel | 24 | $2,054 | $86 |
| Eplerenone | 13 | $1,885 | $145 |
| Metoprolol | 27 | $1,714 | $63 |
| Atorvastatin | 33 | $1,306 | $40 |
| Isosorbide Dinitrate | 15 | $1,291 | $86 |
| Carvedilol | 50 | $899 | $18 |
| Klor-Con M20 | 15 | $878 | $59 |
| Amiodarone | 22 | $592 | $27 |
| Hydralazine | 17 | $313 | $18 |
| Spironolactone | 30 | $264 | $9 |
| Lisinopril | 43 | $254 | $6 |
| Warfarin | 23 | $250 | $11 |
| Furosemide | 41 | $213 | $5 |
| Metoprolol | 33 | $160 | $5 |
| Amlodipine Besylate | 15 | $118 | $8 |
Money from drug and device companies
$473 in 2025
| 2025 | 5 | 7 | None | $473 |
| 2024 | 8 | 9 | None | $518 |
| 2023 | 6 | 9 | None | $538 |
| 2022 | 6 | 14 | None | $1,058 |
| 2021 | 6 | 10 | None | $751 |
| 2020 | 2 | 2 | None | $207 |
| 2019 | 13 | 26 | None | $1,610 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $183 | 2 payments
|
| Abbott Laboratories | Cardiomems | $178 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $74 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $21 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $17 | 1 payment
|
See all 7 published payments
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-17 | Camzyos | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-08 | Jardiance | $89 |
| Abbott Laboratories | Meals · 2025-09-03 | Cardiomems | $153 |
| Merck Sharp & Dohme | Meals · 2025-03-17 | Verquvo | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-12 | None | $74 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-10 | None | $94 |
| Abbott Laboratories | Meals · 2025-01-16 | Thoratec Heartmate 3 Lvas Implant Kit | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $518
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $235 | 2 payments
|
| CVRx | Barostim Neo System | $115 | 1 payment
|
| Abiomed | Impella | $49 | 1 payment
|
| Lexicon Pharmaceuticals | None | $35 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $22 | 1 payment
|
| Pfizer | Vyndaqel | $22 | 1 payment
|
| Recor Medical | Paradise Renal Denervation System | $18 | 1 payment
|
2023: $538
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $162 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $158 | 3 payments
|
| Abiomed | Impella | $108 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $42 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $42 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $26 | 1 payment
|
2022: $1,058
| Abbott Laboratories | Thoratec Heartmate 3 Lvas Implant Kit | $336 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $238 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $161 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $147 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $113 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $62 | 1 payment
|
2021: $751
| Abiomed | Impella | $243 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $192 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $103 | 1 payment
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Assist Device | $102 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $97 | 1 payment
|
| Amgen | None | $14 | 1 payment
|
2020: $207
| Novo Nordisk | None | $124 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $82 | 1 payment
|
2019: $1,610
| Abiomed | Impella | $312 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $270 | 3 payments
|
| Pfizer | Vyndaqel | $159 | 6 payments
|
| Novartis Pharmaceuticals | Entresto | $139 | 3 payments
|
| Alnylam Pharmaceuticals | Onpattro | $125 | 1 payment
|
| Portola Pharmaceuticals | Andexxa | $124 | 1 payment
|
| Maquet Cardiovascular U.S. Sales L.L.C. | Cardiohelp | $124 | 2 payments
|
| Actelion Pharmaceuticals US | Uptravi | $106 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $93 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $84 | 1 payment
|
| Abbott Laboratories | Heartmate | $44 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $19 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · Dapagliflozin in Acute Decompensated Heart Failure · 2022 | Their institution | $24,900 |
| AstraZeneca Pharmaceuticals LP · Dapagliflozin in Acute Decompensated Heart Failure · 2023 | Their institution | $20,795 |
| AstraZeneca Pharmaceuticals LP · Dapagliflozin in Acute Decompensated Heart Failure · 2025 | Their institution | $1,425 |
Professional record
- NPI
- 1013152768
- Licence
- AL L.3009SP, CA F5731
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- AL 01701561, AL 108040, AL 109231, AL 109238, CA 1013152768
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 100 Med Plz, 630, Los Angeles, CA, 90095
- NPI first listed
- 2008-12-10
- NPI last updated
- 2012-09-21
This is when the NPI record was last certified, not a medical board exam.